Gastroenterology Licensing Deal Calculator —
benchmark your deal in 60 seconds
Phase 2 GI deals median ~$60M upfront, ~$700M total. TL1A programs have priced at oncology-level multiples. Built on 1,900+ verified biopharma transactions across 12 therapeutic areas.
Gastroenterology deal benchmarks at a glance
Median deal terms for gastroenterology licensing transactions, by development phase. Data current as of 2026.
| Phase | Median Upfront | Median Total Value | Median Royalty (Tiered) |
|---|---|---|---|
| Preclinical | $20M | $550M | 4–8% |
| Phase 1 | $50M | $900M | 5–10% |
| Phase 2 | $150M | $2B | 7–13% |
| Phase 3 | $400M | $4.2B | 10–18% |
Source: Ambrosia Benchmarker dataset, 1,900+ verified transactions (2017–2026). Primary sources: SEC EDGAR 8-K filings, FTC premerger notifications, ClinicalTrials.gov.
Recent comparable deals
- Roche–Telavant ($7.1B TL1A)
- Pfizer–Arena ($6.7B)
- AbbVie–Pfizer (PROC interlock)
Why Gastroenterology is priced this way
IBD (UC, Crohn’s) drives most GI dealmaking. TL1A, S1P modulators, and oral integrin inhibitors are the active deal categories.
Try it live
Run a Gastroenterology deal scenario
Pick your phase, modality, and indication. Get instant benchmark ranges — no signup needed to start.
Quick Benchmark
Live data from 1,900+ deals. Select your parameters:
Gastroenterology licensing — frequently asked
What is the median upfront payment for a Gastroenterology licensing deal?
How are Gastroenterology deal milestones structured?
What royalty rates are typical for Gastroenterology licensing?
Is there a free Gastroenterology deal calculator?
How does Gastroenterology licensing compare to other therapeutic areas?
7-Day Free Trial · No Promo Code
Run unlimited gastroenterology deals — Pro.
Monte Carlo sensitivity, partner matching across 850+ companies, scenario comparison (Bear/Base/Bull rNPV), and board-ready PDF reports. Free for 7 days. Cancel anytime.
Then $299/month · No charge during trial · Cancel anytime